Author: Claire Cassedy

Two page summary: What does the TPP do as regards prices of drugs and other medical technologies?

Posted on by Claire Cassedy

Attached is a 2 page summary of the main provisions in the Trans-Pacific Partnership Agreement (TPP) that will lead to higher prices for drugs and other medical technologies.

A pdf version of the note is available here: /wp-content/uploads/KEI-TPP-Briefing-2015-2-A2M.pdf

What does the TPP do as regards prices of drugs and other medical technologies?

KEI TPP Briefing note 2015:2
June 10, 2015
Continue Reading →

Sign-on Letter to USTR, be honest about impact of TPP on prices, access to medicines

Posted on by Claire Cassedy

KEI is circulating a sign on letter to be sent to Ambassador Michael Froman of USTR. We learned that in a USTR has been stating that there was no evidence that stronger intellectual property rules created barriers for access to medicine.

This is a shocking statement for USTR to make, and we are seeking confirmation and clarification of USTR’s assertion. The text of our letter follows below.

If you would like to sign on to this letter, please send your name, city and state of residence, and affiliation if any, along with contact details (only for confirmation if necessary), to:

Continue Reading →

KEI Comments to DHHS on WHA68 agenda 11.2, Framework of Engagement with Non-State Actors

Posted on by Claire Cassedy

On Friday May 8, 2015, the US Department of Health and Human Services held a listening session to solicit input on the agenda items for the upcoming 68th World Health Assembly. KEI delivered five interventions covering a range of critical WHA topics. The full provisional agenda of the 68th WHA can be accessed here: http://apps.who.int/gb/ebwha/pdf_files/WHA68/A68_1-en.pdf
jimmy-claire_1024x.png

Continue Reading →

Seminars on Drug Pricing: Part 1, Paul Grootendorst

Posted on by Claire Cassedy

Today, KEI hosted the first talk in a series of seminars on drug pricing. The seminar, conducted via video conference, focused on the Canadian approach to drug pricing. Each seminar in the series is intended to contribute to the discussion on drug pricing and how we can improve affordability and access to medicines. Paul Grootendorst began with a presentation (the slides are available here), before opening up the discussion to questions from those participating in the video conference.

Continue Reading →

KEI Seminars on Drug Pricing: 30 April 2015, Prof. Paul Grootendorst on the Canadian approach to drug pricing

Posted on by Claire Cassedy

On Thursday, 30 April 2015, KEI will host the first talk in a series of seminars on drug pricing. The seminars will take place via video conference (hosted by KEI), and participation is welcome either by attending the presentation at KEI’s Washington, DC offices, or to the extent we are able, joining the digital conference.

Continue Reading →

EB 136 Draft decision passed on the Global Strategy and Plan of Action on Public Health, Innovation, and Intellectual Property

Posted on by Claire Cassedy

On Tuesday February 3, 2015, the final day of the 136th WHO Executive Board meeting, the EB passed a draft decision on the Global Strategy and Plan of Action on Public Health, Innovation, and Intellectual Property (GSPoA). The draft decision recommends to the WHA that the GSPOA be extended until 2022. Continue Reading →

EB 136 Friday, January 30th: Discussion of Consultative Expert Working Group on Research Development-Financing and Coordination

Posted on by Claire Cassedy

Another matter considered during the Friday, January 30th session of the WHO Executive Board was the “Follow-up of the report on the Consultative Expert Working Group on Research Development-Financing and Coordination.” In addition to the general report on the CEWG, the EB also considered the Director General’s report on the CEWG “Health research and development demonstration projects.”

Continue Reading →

EB 136 Friday, January 30th: Global Strategy and Plan of Action on Public Health, Innovation, and Intellectual Property

Posted on by Claire Cassedy

On Friday, January 30th, the WHO Executive Board discussed the Global Strategy and Plan of Action on Public Health, Innovation, and Intellectual Property (GSPA). The discussion covered several documents in relation to the GSPoA, including: